Bank of America: US stocks set a record outflow of $69.5 billion in February, with large inflows into emerging markets and the Asia-Pacific region.
The latest report from Bank of America indicates that investors decisively turned to stocks outside the US in February, signaling a clear differentiation in regional allocation.
Bank of America Corp's latest report states that investors decisively turned to stocks outside the US in February, signaling a clear regional allocation diversification. Active and passive funds collectively saw the most inflows into emerging market stocks, with inflows exceeding $17.6 billion; followed by the Asia Pacific region, with inflows exceeding $14.9 billion. In contrast, US stocks saw the largest outflow of funds, with funds selling $69.5 billion worth of stocks.
By sector, the strongest buying force was in the consumer staples sector, with over $7.9 billion in inflows, followed closely by the materials sector with over $5 billion in inflows, while the software and media sectors saw significant selling, with $17.7 billion and $11 billion respectively.
The report shows that last month, the largest long positions in global stocks were bought in companies such as Walmart Inc. (WMT.US), AbbVie Inc. (ABBV.US), Roche, ASML Holding NV ADR (ASML.US), while the major sell-off stocks included Astrazeneca PLC Sponsored ADR (AZN.US), Microsoft Corporation (MSFT.US), Apple Inc. (AAPL.US), NVIDIA Corporation (NVDA.US).
Bank of America stated that the stocks held by long funds globally were still the most distributed in Taiwan Semiconductor Manufacturing Co., Ltd. Sponsored ADR (TSM.US), with a holding percentage of 92%, followed by ARM (88%), Microsoft Corporation (84%), NVIDIA Corporation (74%), TENCENT (00700) (72%). Stocks with high holding percentages and positive momentum continued to outperform the market, including Broadcom Inc. (AVGO.US), Taiwan Semiconductor Manufacturing Co., Ltd. Sponsored ADR (TSM.US), Samsung Electronics, Micron Technology, Inc. (MU.US), SK Hynix, Eli Lilly and Company (LLY.US).
Related Articles

China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.
China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


